Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q1 2024 call → NOWe need to determine if the transcript shows both halves: (1) real starts narrated as starts, and (2) incomplete climb with printed numbers lagging. Let's examine the transcript. The call is about Q1 2024 results. Management discusses several items: full-thickness skin defects launch, RECELL GO approval pending, PermeaDerm launch, international expansion, etc. Key points: - They mention "distribution agreement with Stedical in early January" - that's a start? But they say "we are encouraged by certain aspects of our business, such as our distribution agreement with Stedical in early January" - but that's just an agreement, not necessarily revenue-generating yet. They later mention "PermeaDerm" launched in U.S. on March 23. That's a product launch. They say "Since the launch of PermeaDerm in the last week of March, our wound care revenue is less than 1%." So that's a start, but it's very small. They also mention "RECELL GO is nearing the end of its 180-day interactive review by the FDA. The 180-day period will end on May 30, 2024. Assuming approval, our top 28 burn accounts will be prioritized for conversion to RECELL GO in June." That's a future launch, not yet started. - They also mention "we are in the validation testing stage of RECELL GO mini" and "we are preparing to submit a PMA supplement for RECELL GO mini in June." That's future. - They talk about "our distribution agreement with Stedical" - but that's just an agreement, not necessarily revenue. They say "we have approximately $3.1 million in inventory that we will recover through future product sales." So that's not yet revenue. - They also mention "we are making progress in our efforts to expand into Australia and most of the European Union through third-party distribution partnerships. We expect to execute distributor agreements in major EU countries and Australia during the remaining part of the year." That's future. - They mention "we are in the validation testing stage of RECELL GO mini" - future. - They mention "our initial six month follow-up assessments of our patients in TONE" - that's a study, not revenue. So what actually started during the period? The PermeaDerm launch in late March. That's a real start. But it's very small (less than 1% of revenue).
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.